{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:25:47Z","timestamp":1790508347529,"version":"4.1.0"},"reference-count":31,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now widely acknowledged as belonging to the broader category of metabolic disorders, being closely associated with obesity, insulin resistance, and chronic systemic inflammation. Recent evidence indicates that in MASLD, alterations in the gut\u2013liver axis\u2014particularly increased intestinal permeability may serve as a crucial mechanistic link between metabolic dysfunction and hepatic steatosis. Zonulin, a physiological modulator of intestinal tight junctions, has been suggested as an indicator of compromised barrier integrity; however, its specific role in MASLD remains to be fully elucidated. Materials and Methods: We conducted a prospective observational study including 52 adult patients diagnosed with MASLD. Hepatic steatosis was evaluated using the SteatoTest (FibroMax panel), while fecal zonulin levels were measured by ELISA at baseline. Clinical, anthropometric, and metabolic parameters were assessed. We used ROC curve analysis to explore zonulin\u2019s predictive value for moderate-to-severe steatosis (\u2265S2). Results: Elevated fecal zonulin (&gt;107 ng\/mL) occurred in 26.9% of participants. In a binary logistic model with SteatoTest \u2265 S2 as outcome, zonulin was independently associated with clinically significant steatosis (OR per 1 ng\/mL = 1.017; 95% CI 1.002\u20131.032; p = 0.029). Discrimination for \u2265S2 was AUC = 0.680 (95% CI 0.535\u20130.825; p = 0.015). The Youden-optimal cut-off was 57.0 ng\/mL (sensitivity 68.2%, specificity 63.3%) versus 40.9%\/83.3% at the manufacturer\u2019s 107 ng\/mL threshold. Conclusions: Fecal zonulin shows modest discriminatory ability for steatosis and is best used as an adjunct to non-invasive assessment; cohort-specific calibration (57.0 ng\/mL) outperformed the generic 107 ng\/mL threshold.<\/jats:p>","DOI":"10.3390\/medicina61091527","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:25:57Z","timestamp":1756189557000},"page":"1527","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3405-4482","authenticated-orcid":false,"given":"Naomi-Adina","family":"Ciurea","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania"},{"name":"Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Monica","family":"Pantea","sequence":"additional","affiliation":[{"name":"Department of Clinical Science-Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-8591","authenticated-orcid":false,"given":"Paul","family":"Grama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-8262","authenticated-orcid":false,"given":"Irina-Bianca","family":"Kosovski","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bataga","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the Global Public Health Agenda for NAFLD: A Consensus Statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 Global NAFLD Prevalence: A Systematic Review and Meta-Analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7570\/jomes22021","article-title":"Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease","volume":"31","author":"Huh","year":"2022","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2516381","DOI":"10.1001\/jamanetworkopen.2025.16381","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease\u2014The New Epidemic of Chronic Liver Disease","volume":"8","author":"Kamath","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yang, Z., Li, A., Jiang, Y., Maidaiti, X., Wu, Y., and Jin, Y. (2024). Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease Attributable to High Fasting Plasma Glucose in 204 Countries and Territories from 1990 to 2021. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-72795-0"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The Gut-Liver Axis and the Intersection with the Microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dai, X., Hou, H., Zhang, W., Liu, T., Li, Y., Wang, S., Wang, B., and Cao, H. (2020). Microbial Metabolites: Critical Regulators in NAFLD. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.567654"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Jiao, Y., Wu, L., Huntington, N.D., and Zhang, X. (2020). Crosstalk Between Gut Microbiota and Innate Immunity and Its Implication in Autoimmune Diseases. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00282"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"M\u00fcnte, E., and Hartmann, P. (2025). The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases. Biomolecules, 15.","DOI":"10.3390\/biom15040469"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00394-018-1784-0","article-title":"Gut Microbiota, Dietary Intakes and Intestinal Permeability Reflected by Serum Zonulin in Women","volume":"57","author":"Lackner","year":"2018","journal-title":"Eur. J. Nutr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s43066-024-00351-6","article-title":"Value of Zonulin as a Diagnostic and Prognostic Marker in Different Degrees of Nonalcoholic Fatty Liver Disease","volume":"14","author":"ElGhandour","year":"2024","journal-title":"Egypt. Liver J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2392864","DOI":"10.1080\/19490976.2024.2392864","article-title":"Changes in Intestinal Permeability and Gut Microbiota Following Diet-Induced Weight Loss in Patients with Metabolic Dysfunction-Associated Steatohepatitis and Liver Fibrosis","volume":"16","author":"Koutoukidis","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Veres-Sz\u00e9kely, A., Sz\u00e1sz, C., Pap, D., Szebeni, B., Bokrossy, P., and Vannay, \u00c1. (2023). Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087548"},{"key":"ref_17","unstructured":"Scheffler, L., Crane, A., Heyne, H., T\u00f6njes, A., Schleinitz, D., Ihling, C.H., Stumvoll, M., Kovacs, P., and Heiker, J.T. (2017). Widely Used Commercial ELISA for Human Zonulin Reacts with Complement C3 Rather than preHaptoglobin2. bioRxiv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1136\/gutjnl-2020-323026","article-title":"Blurring the Picture in Leaky Gut Research: How Shortcomings of Zonulin as a Biomarker Mislead the Field of Intestinal Permeability","volume":"70","author":"Massier","year":"2021","journal-title":"Gut"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Mateos, R., and Albillos, A. (2021). The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.660179"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kessoku, T., Kobayashi, T., Imajo, K., Tanaka, K., Yamamoto, A., Takahashi, K., Kasai, Y., Ozaki, A., Iwaki, M., and Nogami, A. (2021). Endotoxins and Non-Alcoholic Fatty Liver Disease. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.770986"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-021-05188-7","article-title":"The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases","volume":"26","author":"An","year":"2022","journal-title":"J. Gastrointest. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"(2025, July 10). Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Available online: https:\/\/www.mdpi.com\/2227-9059\/10\/1\/83.","DOI":"10.3390\/biomedicines10010083"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, B., Gong, M., Zhu, X., Luo, Y., Li, R., Meng, H., and Wang, Y. (2025). Correlation between Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Insulin Resistance Indicators: A Cross-Sectional Study from NHANES 2017\u20132020. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1514093"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/liv.14696","article-title":"Intestinal Permeability in Human Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Di Zeo-S\u00e1nchez, D.E., D\u00edaz-Alberola, I., Pinazo-Bandera, J.M., Garc\u00eda-Cort\u00e9s, M., Sanabria-Cabrera, J., Robles-D\u00edaz, M., \u00c1lvarez-\u00c1lvarez, I., Lucena, M.I., Andrade, R.J., and Villanueva-Paz, M. (2025). Intestinal Permeability and Immune-Inflammatory Markers in Patients with Idiosyncratic Drug-Induced Liver Injury, Drug-Induced Steatosis and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Br. J. Pharmacol.","DOI":"10.1111\/bph.70123"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the Barriers: The Role of Gut Homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Cubero","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wei, L., Yue, F., Xing, L., Wu, S., Shi, Y., Li, J., Xiang, X., Lam, S.M., Shui, G., and Russell, R. (2020). Constant Light Exposure Alters Gut Microbiota and Promotes the Progression of Steatohepatitis in High Fat Diet Rats. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01975"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jiacheng, X., Guochu, H., Minhang, L., Yinhang, C., Yu, Z., Xia, Z., Jingyun, Y., Meiwen, T., Weisheng, L., and Xiaocong, M. (2025). The Interventional Role and Mechanism of Total Flavonoids in Lychee Seeds on Rats with Liver Fibrosis. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-10007-z"},{"key":"ref_29","first-page":"619","article-title":"Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Coste, S.-C., Or\u0103\u0219an, O.H., Cozma, A., Negrean, V., Sitar-T\u0103ut, A.-V., Filip, G.A., Hangan, A.C., Lucaciu, R.L., Iancu, M., and Procopciuc, L.M. (2024). Metabolic Dysfunction-Associated Steatotic Liver Disease: The Associations between Inflammatory Markers, TLR4, and Cytokines IL-17A\/F, and Their Connections to the Degree of Steatosis and the Risk of Fibrosis. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092144"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107780","DOI":"10.1016\/j.phrs.2025.107780","article-title":"Reinforcing Gut Integrity: A Systematic Review and Meta-Analysis of Clinical Trials Assessing Probiotics, Synbiotics, and Prebiotics on Intestinal Permeability Markers","volume":"216","author":"Ghorbani","year":"2025","journal-title":"Pharmacol. Res."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1527\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:32:38Z","timestamp":1760034758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091527"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091527","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}